Exploratory subset analysis of African Americans from the PointBreak study: Pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB/IV nonsquamous non-small-cell lung cancer
Craig H. Reynolds*, Jyoti D. Patel, Edward B. Garon, Mark R. Olsen, Philip Bonomi, Ramaswamy Govindan, Eduardo J. Pennella, Jingyi Liu, Susan C. Guba, Shi Li, David R. Spigel, Robert C. Hermann, Mark A. Socinski, Coleman K. Obasaju
Dive into the research topics of 'Exploratory subset analysis of African Americans from the PointBreak study: Pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB/IV nonsquamous non-small-cell lung cancer'. Together they form a unique fingerprint.